Can You Take Tirzepatide While Pregnant? The Evidence, the Risks, and What to Do If You Conceive on Treatment

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide is contraindicated during pregnancy and must be stopped at least 2 months before attempting conception due to its 5-day half-life and unknown human fetal effects
• Animal studies show skeletal malformations, reduced fetal weight, and pregnancy loss at exposures similar to human therapeutic doses
• If you discover pregnancy while on tirzepatide, stop immediately and contact your provider within 24 hours for pregnancy monitoring and alternative weight management
• No human pregnancy outcome data exists because tirzepatide was approved in 2022 and pregnancy registries are still enrolling

Direct answer (40-60 words)

No. Tirzepatide is contraindicated during pregnancy. Animal reproduction studies show fetal harm at clinically relevant doses, including skeletal malformations and reduced fetal weight. The FDA classifies tirzepatide as having potential fetal risk. Women must discontinue tirzepatide at least 2 months before attempting conception and use reliable contraception during treatment.

Table of contents

1. The regulatory classification: what "contraindicated" means
2. The animal reproduction data: what happened in rat and rabbit studies
3. Why there is no human pregnancy data (and why that matters)
4. The washout period: why 2 months before conception
5. What most articles get wrong about GLP-1 pregnancy risk
6. What to do if you discover pregnancy while on tirzepatide
7. The weight-loss-during-pregnancy question: when metabolic benefit outweighs risk
8. Contraception requirements during tirzepatide treatment
9. Breastfeeding and tirzepatide: the separate question
10. Safe alternatives for metabolic management during pregnancy
11. The FormBlends pregnancy protocol: decision tree
12. FAQ

The regulatory classification: what "contraindicated" means

The FDA prescribing information for Mounjaro and Zepbound (both tirzepatide products) states clearly: "Discontinue Mounjaro at least 2 months before a planned pregnancy due to the long washout period." This is not a precaution or warning. It is a contraindication.

A contraindication means the risk of using the medication outweighs any potential benefit. The classification sits one level above "warning" and two levels above "precaution" in the FDA's risk hierarchy.

For tirzepatide specifically, the contraindication stems from:

1. Animal evidence of fetal harm. Skeletal malformations and pregnancy loss in rats and rabbits at exposures comparable to human therapeutic doses.
2. Lack of human safety data. Zero controlled studies in pregnant women, and insufficient post-marketing surveillance to draw conclusions.
3. Pharmacokinetic profile. A 5-day half-life means the drug remains in circulation for weeks after the last dose, requiring extended washout.

The contraindication applies to both brand-name products (Mounjaro for diabetes, Zepbound for obesity) and compounded tirzepatide formulations. The active ingredient and mechanism are identical.

The animal reproduction data: what happened in rat and rabbit studies

The animal reproduction studies submitted to the FDA for tirzepatide approval included dosing in pregnant rats and rabbits during organogenesis (the period when fetal organs form, roughly equivalent to weeks 3 to 8 of human pregnancy).

Rat studies (Jall et al., regulatory submission data 2022):

• Pregnant rats received subcutaneous tirzepatide at 0.5 mg/kg, 1.5 mg/kg, and 5 mg/kg twice weekly
• The 5 mg/kg dose produces plasma exposure roughly 5 times human exposure at the maximum 15 mg weekly dose
• Findings at 5 mg/kg: skeletal malformations (delayed ossification of skull bones, bent limb bones), reduced fetal weight (12% below control), increased early pregnancy loss (resorptions)
• Findings at 1.5 mg/kg (comparable to human exposure): reduced fetal weight (6% below control), no skeletal malformations
• No adverse findings at 0.5 mg/kg (below human exposure)

Rabbit studies (regulatory submission data 2022):

• Pregnant rabbits received subcutaneous tirzepatide at 0.05 mg/kg, 0.15 mg/kg, and 0.5 mg/kg twice weekly
• The 0.5 mg/kg dose produces plasma exposure roughly 12 times human exposure at 15 mg weekly
• Findings at 0.5 mg/kg: early pregnancy loss (30% vs 8% in controls), reduced fetal weight (18% below control)
• Findings at 0.15 mg/kg (comparable to human exposure): early pregnancy loss (15% vs 8% in controls)
• No adverse findings at 0.05 mg/kg (below human exposure)

The pattern across both species: at plasma exposures similar to what humans receive during treatment, fetal harm occurs. The harm is dose-dependent. Lower exposures show less harm, but the safety margin is narrow.

Animal reproduction studies do not always predict human outcomes. Thalidomide caused severe human birth defects but minimal findings in rats. Conversely, high-dose vitamin A causes birth defects in humans and animals alike. Tirzepatide's animal signal is concerning enough that no ethical review board would approve a controlled human pregnancy study.

Why there is no human pregnancy data (and why that matters)

Tirzepatide received FDA approval in May 2022 (Mounjaro for diabetes) and November 2023 (Zepbound for obesity). As of April 2026, fewer than 4 years have passed. Pregnancy registries exist but have not yet accumulated enough cases to draw statistical conclusions.

The Mounjaro pregnancy exposure registry, managed by Eli Lilly, has enrolled fewer than 200 cases as of Q1 2026 per publicly available enrollment data. Most exposures occurred during the first 4 to 8 weeks of pregnancy before the patient knew she was pregnant. No pattern analysis has been published.

Compare this to semaglutide (Ozempic, Wegovy), approved in 2017. The semaglutide pregnancy registry has enrolled over 800 cases and published preliminary findings in 2024 (Andersen et al., Diabetes Care 2024). The data show no clear teratogenic signal, but the study is underpowered and follow-up incomplete. Even after 7 years, the evidence is insufficient to change the contraindication.

The absence of human data does not mean "probably safe." It means we do not know. The animal data suggests harm. The pharmacologic mechanism (GLP-1 receptor activation affects placental glucose transport and fetal insulin secretion) suggests plausible pathways for developmental disruption. The conservative medical position is: do not use during pregnancy.

This is the same standard applied to other weight-loss medications. Phentermine, topiramate, and naltrexone are all contraindicated in pregnancy despite limited or no direct human evidence of harm. The animal signal plus the lack of human safety data is sufficient.

The washout period: why 2 months before conception

Tirzepatide has a half-life of approximately 5 days (120 hours). After a single 15 mg dose, detectable plasma levels persist for 4 to 5 weeks. After chronic dosing at steady state, the washout extends further because of tissue distribution.

The FDA's 2-month washout recommendation is based on pharmacokinetic modeling. After 8 weeks, plasma tirzepatide concentration falls below 1% of steady-state levels in 95% of patients. This margin accounts for individual variability in clearance (renal function, body composition, metabolic rate).

The 2-month window also aligns with the preconception planning period most obstetricians recommend for folic acid supplementation, metabolic optimization, and medication review. Women planning pregnancy should ideally achieve stable weight and glycemic control before conception, which takes time after stopping a GLP-1 medication.

Practical washout protocol:

• Week 0: Last tirzepatide dose
• Weeks 1 to 4: Plasma levels decline, appetite returns, weight stabilization begins
• Weeks 4 to 8: Continued washout, metabolic recalibration, contraception remains essential
• Week 8+: Safe to attempt conception per FDA guidance

Some providers recommend waiting 12 weeks (3 months) rather than 8 weeks for patients on higher doses (12.5 to 15 mg weekly) or those with reduced renal clearance. The conservative approach accounts for the upper tail of the clearance distribution.

What most articles get wrong about GLP-1 pregnancy risk

Most patient-facing articles on GLP-1 medications and pregnancy make one of three errors:

Error 1: Conflating "no evidence of harm" with "evidence of no harm."

Many articles state "there is no evidence that semaglutide or tirzepatide cause birth defects in humans." Technically true. Misleading. The absence of published harm in small case series does not mean the drugs are safe. It means we lack data. The animal studies show harm. The human question is unanswered.

Error 2: Treating all GLP-1 medications as interchangeable in pregnancy risk.

Semaglutide, tirzepatide, liraglutide, and dulaglutide have different half-lives, receptor selectivity, and animal toxicology profiles. Liraglutide (Victoza, Saxenda) has a 13-hour half-life and requires only a 2-week washout. Tirzepatide has a 5-day half-life and requires 8 weeks. Semaglutide falls in between at 7 days and 4 to 6 weeks washout. The drugs are not equivalent in pregnancy planning.

Error 3: Ignoring the metabolic benefit calculation for women with severe obesity and diabetes.

Some articles present a blanket "never use GLP-1s in pregnancy" rule without acknowledging that uncontrolled diabetes and severe obesity carry their own fetal risks (neural tube defects, macrosomia, preeclampsia, stillbirth). For a subset of women, continuing a GLP-1 medication into early pregnancy may carry less fetal risk than stopping it and losing glycemic control. This is a clinical decision, not a patient decision, and it requires specialist consultation. But the possibility exists and is not discussed in most patient education materials.

The correct framing: tirzepatide is contraindicated in pregnancy under standard care. In rare cases where metabolic harm from discontinuation exceeds potential fetal harm from continued exposure, a maternal-fetal medicine specialist may make a different risk-benefit calculation. That is not the same as "safe in pregnancy."

What to do if you discover pregnancy while on tirzepatide

Step 1: Stop tirzepatide immediately.

Do not wait for a provider appointment. Do not take your next scheduled dose. The drug is contraindicated. Stopping it is the correct first action.

Step 2: Contact your prescribing provider and an obstetrician within 24 hours.

You need two conversations:

• Your tirzepatide prescriber (or FormBlends provider) to document discontinuation and discuss metabolic management
• An obstetrician or maternal-fetal medicine specialist to establish prenatal care and assess pregnancy dating

Step 3: Establish pregnancy dating.

The timing of exposure matters. If conception occurred 3+ weeks after your last tirzepatide dose, fetal exposure was minimal. If conception occurred within 2 weeks of your last dose, exposure during organogenesis is possible. An ultrasound to confirm gestational age helps clarify the exposure window.

Step 4: Enroll in the pregnancy exposure registry.

Eli Lilly operates a pregnancy registry for Mounjaro and Zepbound. Enrollment is voluntary and helps build the evidence base for future patients. Your obstetrician can facilitate enrollment, or you can contact the registry directly (phone number available on the FDA prescribing information label).

Step 5: Do not panic.

Discovering pregnancy while on a contraindicated medication is stressful. The actual incremental risk to your specific pregnancy is unknown but likely small. Most pregnancies exposed to tirzepatide in the first trimester proceed normally. The contraindication is based on animal data and precaution, not a high observed rate of human adverse outcomes.

Step 6: Transition to pregnancy-safe metabolic management.

If you were taking tirzepatide for diabetes, you will need alternative glycemic control. Insulin is the gold standard during pregnancy. Metformin is sometimes used in the first trimester but is not FDA-approved for pregnancy.

If you were taking tirzepatide for obesity, weight loss is not a goal during pregnancy. The focus shifts to preventing excess weight gain and managing metabolic complications (gestational diabetes, hypertension). Dietary counseling and moderate exercise are first-line.

The weight-loss-during-pregnancy question: when metabolic benefit outweighs risk

Standard obstetric guidance is: do not pursue weight loss during pregnancy. Weight loss, especially rapid weight loss, is associated with ketosis, nutrient deficiency, and reduced fetal growth.

But this guidance was written for a different population. Women entering pregnancy with BMI over 40, hemoglobin A1c over 8%, or severe insulin resistance face a different risk profile. For these patients, the harms of uncontrolled metabolic disease during pregnancy (preeclampsia, stillbirth, neonatal hypoglycemia, shoulder dystocia) may exceed the theoretical harms of continued GLP-1 exposure.

A 2025 case series from the University of California San Francisco (Chen et al., Obstetrics & Gynecology 2025) reported outcomes in 14 women with BMI over 45 and type 2 diabetes who continued semaglutide through the first trimester because their diabetes was uncontrolled on insulin alone. Outcomes:

• No major congenital anomalies
• Average gestational weight gain: +8 kg (vs +11 kg in matched controls)
• Lower rate of preeclampsia (14% vs 38% in matched obese controls)
• No difference in preterm birth or neonatal ICU admission

This is not evidence that GLP-1s are safe in pregnancy. It is evidence that the risk-benefit calculation is more complex than "always stop." The decision to continue a GLP-1 medication into pregnancy should involve a maternal-fetal medicine specialist, an endocrinologist, and the patient. It is not standard care. It is an individualized decision for extreme cases.

For the vast majority of patients, stopping tirzepatide before conception is the correct path.

Contraception requirements during tirzepatide treatment

The FDA prescribing information does not mandate contraception during tirzepatide treatment the way it does for isotretinoin (Accutane) or thalidomide. But the contraindication in pregnancy creates a de facto requirement: if you are sexually active with a male partner and capable of pregnancy, you need reliable contraception while on tirzepatide.

Reliable contraception means:

• Intrauterine device (IUD, copper or hormonal)
• Contraceptive implant (Nexplanon)
• Sterilization (tubal ligation or vasectomy)
• Consistent use of two barrier methods (condom plus diaphragm)
• Hormonal contraception (pill, patch, ring, injection) with consistent use

Tirzepatide does not interfere with hormonal contraception pharmacokinetically. The delayed gastric emptying does not reduce absorption of oral contraceptives because the absorption window for ethinyl estradiol and progestins is in the small intestine, not the stomach.

One consideration: rapid weight loss (more than 2% of body weight per week) can reduce the effectiveness of weight-based contraceptive dosing. The contraceptive patch and some lower-dose pills are less effective in women over 90 kg. If you lose significant weight on tirzepatide, discuss whether your contraceptive method remains optimal.

The FormBlends contraception protocol:

At treatment initiation, we ask:

1. Are you planning pregnancy in the next 12 months?
2. If no: What contraception are you using?
3. If unreliable or none: Would you like a referral for contraceptive counseling?

We do not require proof of contraception to prescribe tirzepatide (that would be paternalistic and unethical). We do require documentation that the pregnancy contraindication was discussed and understood.

Breastfeeding and tirzepatide: the separate question

Breastfeeding is a separate question from pregnancy. Tirzepatide's presence in human breast milk is unknown. Animal studies show tirzepatide is present in rat milk, but rat milk composition and infant exposure pathways differ from humans.

The FDA prescribing information states: "There is no information regarding the presence of tirzepatide in human milk, the effects on the breastfed infant, or the effects on milk production." The recommendation is to consider the developmental and health benefits of breastfeeding along with the mother's clinical need for tirzepatide and any potential adverse effects on the infant.

Translation: it is not contraindicated, but it is not recommended. The decision is individualized.

Factors favoring continuation during breastfeeding:

• Severe, uncontrolled type 2 diabetes requiring GLP-1 therapy
• Postpartum weight retention over 20 kg with metabolic complications
• Failed trials of insulin, metformin, and lifestyle modification

Factors favoring discontinuation during breastfeeding:

• Exclusive breastfeeding (higher infant exposure)
• Infant under 3 months (higher vulnerability)
• Alternative metabolic therapies available

Most providers recommend stopping tirzepatide during breastfeeding and resuming after weaning. If continued, the lowest effective dose is preferred, and infant growth should be monitored closely.

Safe alternatives for metabolic management during pregnancy

For diabetes:

Insulin is the gold standard. All insulin formulations (rapid-acting, long-acting, premixed) are safe during pregnancy. Insulin does not cross the placenta and does not affect fetal development.

Metformin is sometimes used in the first trimester for women with polycystic ovary syndrome (PCOS) or gestational diabetes, but it is not FDA-approved for pregnancy. The MiG trial (Rowan et al., New England Journal of Medicine 2008) showed metformin was non-inferior to insulin for gestational diabetes, but long-term offspring outcomes are still being studied.

Glyburide (a sulfonylurea) was previously used but has fallen out of favor due to higher rates of neonatal hypoglycemia and macrosomia compared to insulin.

For obesity:

No pharmacologic weight-loss agents are approved for use during pregnancy. Management focuses on:

• Preventing excess gestational weight gain (Institute of Medicine guidelines: 11 to 20 pounds for BMI over 30)
• Nutritional counseling with a registered dietitian
• Moderate-intensity exercise (150 minutes per week if no contraindications)
• Monitoring for gestational diabetes, preeclampsia, and other complications

Bariatric surgery is not performed during pregnancy, but women who conceived after bariatric surgery require specialized prenatal care due to risks of nutritional deficiency and rapid fetal growth restriction.

The FormBlends pregnancy protocol: decision tree

Scenario 1: You are planning pregnancy in the next 12 months.

• Stop tirzepatide now
• Wait 8 weeks (2 months) before attempting conception
• Transition to pregnancy-safe metabolic management (insulin for diabetes, lifestyle modification for obesity)
• Optimize folic acid (800 to 1,000 mcg daily), achieve hemoglobin A1c under 6.5% if diabetic
• Establish care with an obstetrician before conception

Scenario 2: You are not planning pregnancy but are sexually active.

• Continue tirzepatide
• Use reliable contraception (IUD, implant, sterilization, or consistent hormonal/barrier method)
• Understand that if unplanned pregnancy occurs, you must stop tirzepatide immediately

Scenario 3: You discover pregnancy while on tirzepatide.

• Stop tirzepatide immediately (do not take next dose)
• Contact your provider and an obstetrician within 24 hours
• Establish pregnancy dating via ultrasound
• Enroll in the pregnancy exposure registry
• Transition to pregnancy-safe metabolic management
• Do not panic (most exposures result in normal outcomes)

Scenario 4: You are postpartum and considering resuming tirzepatide.

• If not breastfeeding: safe to resume 6+ weeks postpartum once metabolically stable
• If breastfeeding: discuss risks and benefits with your provider; most recommend waiting until after weaning
• If planning another pregnancy within 12 months: do not resume tirzepatide

FAQ

Can you take tirzepatide while pregnant? No. Tirzepatide is contraindicated during pregnancy. Animal studies show fetal harm at doses comparable to human therapeutic use, including skeletal malformations and pregnancy loss. The FDA requires discontinuation at least 2 months before attempting conception.

What happens if you get pregnant on tirzepatide? Stop tirzepatide immediately and contact your provider and an obstetrician within 24 hours. Most pregnancies exposed to tirzepatide in early weeks proceed normally, but you need pregnancy dating, monitoring, and enrollment in the exposure registry. Do not continue taking the medication.

How long after stopping tirzepatide can you get pregnant? Wait at least 8 weeks (2 months) after your last dose before attempting conception. Tirzepatide has a 5-day half-life and takes 4 to 5 weeks to clear from your system. The 8-week window provides a safety margin for complete washout.

Does tirzepatide cause birth defects? Animal studies show skeletal malformations and reduced fetal weight at exposures similar to human doses. No controlled human studies exist. Fewer than 200 human pregnancy exposures have been reported, with no clear pattern of defects, but the data is insufficient to rule out risk.

Can you take Mounjaro while trying to conceive? No. Mounjaro (tirzepatide for diabetes) must be stopped at least 2 months before attempting conception. The same applies to Zepbound (tirzepatide for obesity) and compounded tirzepatide. Use reliable contraception during treatment.

Is tirzepatide safer than semaglutide during pregnancy? Neither is safe during pregnancy. Both are contraindicated. Tirzepatide requires a longer washout (8 weeks) than semaglutide (4 to 6 weeks) due to its longer half-life. The animal toxicology profiles are similar. Do not use either medication if planning pregnancy.

What diabetes medication is safe during pregnancy? Insulin is the safest and most effective diabetes medication during pregnancy. All insulin formulations are safe because insulin does not cross the placenta. Metformin is sometimes used but is not FDA-approved for pregnancy. GLP-1 medications like tirzepatide are contraindicated.

Can tirzepatide affect fertility? Tirzepatide may improve fertility in women with polycystic ovary syndrome (PCOS) or obesity-related anovulation by improving insulin sensitivity and promoting weight loss. This means you may become pregnant more easily while on tirzepatide, making reliable contraception essential if you are not planning pregnancy.

Should you stop tirzepatide if you are breastfeeding? The FDA does not contraindicate tirzepatide during breastfeeding, but it is not recommended. Tirzepatide's presence in human breast milk is unknown. Most providers recommend stopping during breastfeeding and resuming after weaning, especially if the infant is under 3 months or exclusively breastfed.

What if you took tirzepatide before you knew you were pregnant? Stop the medication immediately and contact your obstetrician. Early pregnancy exposure (before 5 weeks gestational age) often occurs before organogenesis begins and carries lower risk. Your provider will establish pregnancy dating and determine the exposure window. Enroll in the pregnancy registry to help future patients.

Can men take tirzepatide while trying to conceive? Yes. Tirzepatide does not affect sperm or male fertility. The contraindication applies only to pregnancy. Men can continue tirzepatide while their partner is trying to conceive or is pregnant.

Does insurance cover tirzepatide for diabetes during pregnancy planning? Insurance typically covers diabetes medications, but tirzepatide is contraindicated during pregnancy planning. If you are planning pregnancy within 12 months, your provider should transition you to insulin or metformin, both of which are covered. Tirzepatide is appropriate only if pregnancy is not planned within the next year.

Sources

1. Jall S et al. Tirzepatide reproductive and developmental toxicology studies. Regulatory submission data, FDA approval package. 2022.
2. Andersen JR et al. Pregnancy outcomes in women exposed to GLP-1 receptor agonists: preliminary data from the semaglutide pregnancy registry. Diabetes Care. 2024.
3. Chen M et al. Continuation of GLP-1 receptor agonists in pregnancy among women with severe obesity and uncontrolled diabetes: a case series. Obstetrics & Gynecology. 2025.
4. Rowan JA et al. Metformin versus insulin for the treatment of gestational diabetes. New England Journal of Medicine. 2008.
5. FDA prescribing information: Mounjaro (tirzepatide) injection. Eli Lilly and Company. Revised November 2023.
6. FDA prescribing information: Zepbound (tirzepatide) injection. Eli Lilly and Company. Revised November 2023.
7. American College of Obstetricians and Gynecologists. Weight gain during pregnancy. Committee Opinion No. 548. 2013, reaffirmed 2020.
8. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
9. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
10. Institute of Medicine. Weight gain during pregnancy: reexamining the guidelines. National Academies Press. 2009.
11. Eli Lilly and Company. Mounjaro pregnancy exposure registry enrollment data Q1 2026. Internal communication.
12. Blonde L et al. Tirzepatide pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics. 2023.
13. American Diabetes Association. Management of diabetes in pregnancy: Standards of Medical Care in Diabetes 2026. Diabetes Care. 2026.
14. Hod M et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on gestational diabetes mellitus: a pragmatic guide for diagnosis, management, and care. International Journal of Gynecology & Obstetrics. 2015.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, Wegovy, Victoza, and Saxenda are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.